Amgen Inc. Canadian Depositary Receipt logo

Amgen Inc. Canadian Depositary Receipt (AMGN)

Market Closed
NEO-L NEO-L
CA$
CA$
- Market Cap
19.61 P/E Ratio
0.07% Div Yield
- Volume
18.58 Eps
CA$
Previous Close
Add Transaction
Day Range
0 0
Year Range
0 0
Want to track AMGN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

AMGN is not paying dividends to its shareholders.
The last earnings report, released on Apr 29, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on TSX (CAD).

AMGN Chart

Amgen Inc. Canadian Depositary Receipt (AMGN) FAQ

What is the stock price today?

The current price is CA$0.00.

On which exchange is it traded?

Amgen Inc. Canadian Depositary Receipt is listed on NEO-L.

What is its stock symbol?

The ticker symbol is AMGN.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.07%.

What is its market cap?

As of today, no market cap data is available.

Has Amgen Inc. Canadian Depositary Receipt ever had a stock split?

No, there has never been a stock split.

Amgen Inc. Canadian Depositary Receipt Profile

Biotechnology Industry
Healthcare Sector
Robert A. Bradway CEO
NEO-L Exchange
- ISIN
US Country
28,000 Employees
- Last Dividend
- Last Split
17 Jun 1983 IPO Date

Overview

Amgen Inc. is a global leader in biotechnology, focusing on the discovery, development, manufacture, and delivery of human therapeutics. The company has a comprehensive portfolio of treatment options targeting various diseases and conditions, ranging from oncology and osteoporosis to cardiovascular diseases and inflammatory disorders. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen serves healthcare providers worldwide, including physicians' clinics, dialysis centers, hospitals, and pharmacies. Its distribution network encompasses pharmaceutical wholesale distributors and direct-to-consumer channels. Amgen’s collaborative efforts extend to several high-profile partnerships with other pharmaceutical giants, including AstraZeneca, Novartis Pharma AG, UCB, Kyowa Kirin Co., Ltd., and BeiGene, Ltd., aiming at the expansion and development of innovative therapies.

Products and Services

  • Enbrel - A leading therapy for plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis.
  • Otezla - Designed for adults suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease.
  • Prolia - Addresses osteoporosis in postmenopausal women.
  • XGEVA - Prevents skeletal-related events.
  • Repatha - Reduces the risk of myocardial infarction, stroke, and coronary revascularization.
  • Nplate - Treats immune thrombocytopenia.
  • KYPROLIS - For relapsed or refractory multiple myeloma patients.
  • Aranesp - Addresses a lower-than-normal number of red blood cells and anemia.
  • EVENITY - A treatment for osteoporosis in postmenopausal for men and women.
  • Vectibix - Treats patients with wild-type RAS metastatic colorectal cancer.
  • BLINCYTO - For patients with acute lymphoblastic leukemia.
  • TEPEZZA - Treats thyroid eye disease.
  • KRYSTEXXA - Addresses chronic refractory gout.
  • Additional Products - Amgen also markets Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA, and PROCYSBI, covering a wide range of therapeutic areas.

Contact Information

Address: One Amgen Center Drive
Phone: 805 447 1000